Pure Global

A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients - Trial NCT05773586

Access comprehensive clinical trial information for NCT05773586 through Pure Global AI's free database. This Phase 1 trial is sponsored by Ascentage Pharma Group Inc. and is currently Recruiting. The study focuses on Anemia. Target enrollment is 115 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05773586
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05773586
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Investigate the Safety, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients
A Phase 1 Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalating Study to Evaluate Safety and Tolerability, Pharmacokinetics and Efficacy of APG-5918 in Healthy Subjects or Anemic Patients

Study Focus

Anemia

APG-5918

Interventional

drug

Sponsor & Location

Ascentage Pharma Group Inc.

Guangzhou, China

Timeline & Enrollment

Phase 1

Mar 15, 2023

Mar 15, 2026

115 participants

Primary Outcome

Treatment-Emergent Adverse Events (TEAEs)

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and
 efficacy of APG-5918 in Healthy Subjects or Anemic Patients.

ICD-10 Classifications

Anaemia, unspecified
Other anaemias
Other specified anaemias
Iron deficiency anaemia
Iron deficiency anaemia, unspecified

Data Source

ClinicalTrials.gov

NCT05773586

Non-Device Trial